We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+105.87%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$319M
AUM Growth
+$150M
Cap. Flow
+$43.8M
Cap. Flow %
13.73%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
APTX
Aptinyx Inc. Common Stock
APTX
+$47.6M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$3.81M

Sector Composition

Rank Sector Weight
1 Healthcare 56.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DRNA
1
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$109M 34.28%
8,930,237
– –
SLDB icon
2
Solid Biosciences
SLDB
$841M
$70.9M 22.21%
132,630
– –
IFRX icon
3
InflaRx
IFRX
$280M
$57M 17.85%
1,766,038
-110,375
-6% -$3.81M
APTX
4
DELISTED
Aptinyx Inc. Common Stock
APTX
$53.8M 16.85%
+2,225,092
New +$47.6M
MRNS
5
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$28.1M 8.81%
994,363
– –

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q2 2018 Portfolio in Review

As of Q2 2018, Bain Capital Life Sciences Investors held 5 positions worth $319M, up 88% from $170M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Bain Capital Life Sciences Investors deployed $43.8M of net new capital in Q2 2018, opening 1 new position. Its largest new stake was Aptinyx Inc. Common Stock: 2,225,092 shares worth $53.8M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 41% a quarter earlier.

On the sell side, the largest reduction was InflaRx, an estimated $3.81M trimmed.

  • Bain Capital Life Sciences Investors's largest Q2 2018 buy was Aptinyx Inc. Common Stock: 2,225,092 shares worth $53.8M.
  • Bain Capital Life Sciences Investors's biggest Q2 2018 reduction was InflaRx, cutting an estimated $3.81M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 100% of its $319M portfolio in Q2 2018.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 0 in Q2 2018.
  • Bain Capital Life Sciences Investors's portfolio value rose 88% quarter-over-quarter to $319M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2018, filed 14 Aug 2018.